MindBio Therapeutics (XCNQ:MBIO) Long-Term Debt : C$3.55 Mil (As of Mar. 2024)

View and export this data going back to 2023. Start your Free Trial

What is MindBio Therapeutics Long-Term Debt?

MindBio Therapeutics's Long-Term Debt for the quarter that ended in Mar. 2024 was C$3.55 Mil.

MindBio Therapeutics's quarterly Long-Term Debt increased from Sep. 2023 (C$2.45 Mil) to Dec. 2023 (C$3.54 Mil) and increased from Dec. 2023 (C$3.54 Mil) to Mar. 2024 (C$3.55 Mil).

MindBio Therapeutics's annual Long-Term Debt increased from Jun. 2021 (C$0.00 Mil) to Jun. 2022 (C$4.05 Mil) but then declined from Jun. 2022 (C$4.05 Mil) to Jun. 2023 (C$2.51 Mil).

MindBio Therapeutics Long-Term Debt Historical Data

The historical data trend for MindBio Therapeutics's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MindBio Therapeutics Long-Term Debt Chart

MindBio Therapeutics Annual Data

Trend

Jun21

Jun22

Jun23

Long-Term Debt

4.05

2.51

MindBio Therapeutics Quarterly Data
	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Long-Term Debt	Get a 7-Day Free Trial					4.17	2.51	2.45	3.54	3.55

MindBio Therapeutics (XCNQ:MBIO) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

MindBio Therapeutics Long-Term Debt Related Terms

Thank you for viewing the detailed overview of MindBio Therapeutics's Long-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

MindBio Therapeutics (XCNQ:MBIO) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MindBio Therapeutics Corp (XCNQ:MBIO) » Definitions » Long-Term Debt

Comparable Companies

Traded in Other Exchanges

WF6:Germany

Address

91-97 William Street, Level 4, Melbourne, VIC, AUS, 3000

Website

https://www.mindbiotherapeutics.com

MindBio Therapeutics Corp is pioneering clinical studies into the microdosing of psychedelic medicines to treat a range of medical conditions such as depression, anxiety, PTSD, panic disorder, chronic pain and opiate addictions. Its clinical trials microdosing of psychedelic medicines provide hope for sufferers of mental health conditions with new emerging treatment alternatives. The company invests in clinical research to discover potential new treatment options and aims to create novel medicines and treatment regimes from breakthrough microdosing studies. Geographically, the activities of the company takes place in Australia.